Orient Pharma Co., Ltd. (TPEX:4166)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
26.15
+1.30 (5.23%)
Dec 31, 2025, 1:30 PM CST
-27.36%
Market Cap6.36B
Revenue (ttm)1.28B
Net Income (ttm)127.99M
Shares Out243.04M
EPS (ttm)0.57
PE Ratio46.05
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume454,033
Average Volume150,290
Open25.00
Previous Close24.85
Day's Range25.00 - 26.15
52-Week Range22.30 - 41.45
Beta0.05
RSI63.70
Earnings DateMar 20, 2026

About Orient Pharma

Orient Pharma Co., Ltd. engages in the research and development, manufacturing, and sales of drugs in Taiwan and internationally. The company develops anti-psychotics and psychostimulants, as well as drugs for treating Parkinson’s and Alzheimer’s diseases; and products for the treatment of sialorrhea, tuberculosis, and attention deficit hyperactivity disorder. It is also developing drug delivery technologies, such as multi-stages-controlled release technology, trans-dermal patches, oral disintegrating tablets, sustained release technology, and ... [Read more]

Sector Healthcare
Founded 2008
Employees 173
Stock Exchange Taipei Exchange
Ticker Symbol 4166
Full Company Profile

Financial Performance

In 2024, Orient Pharma's revenue was 1.22 billion, an increase of 37.41% compared to the previous year's 889.91 million. Earnings were 107.37 million, an increase of 381.76%.

Financial Statements

News

There is no news available yet.